Avtor/Urednik		Žist, Andrej; Amir, Eitan; Ocaña, Alberto; Šeruga, Boštjan
Naslov		Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel
Tip		članek
Vol. in št.		Letnik 49, št. 4
Leto izdaje		2015
Obseg		str. 402-408
ISSN		1318-2099 - Radiology and oncology
Jezik		eng
Abstrakt		Men with metastatic castrate-resistant prostate cancer (mCRPC) may not receive docetaxel in everyday clinical practice due to comorbidities. Here we explore the impact of comorbidity on outcome in men with mCRPC treated with docetaxel in a population-based outcome study. Methods. Men with mCRPC treated with docetaxel at the Institute of Oncology Ljubljana between 2005 and 2012 were eligible. Comorbidity was assessed by the age-adjusted Charlson comorbidity index (aa-CCI) and adult comorbidity evaluation (ACE-27) index. Hospital admissions due to the toxicity and deaths during treatment with docetaxel were used as a measure of tolerability. Association between comorbidity and overall survival (OS) was tested using the Cox proportional hazards analysis. Results. Two hundred and eight men were treated with docetaxel. No, mild, moderate and severe comorbidity was present in 2%, 32%, 53% and 13% using aa-CCI and in 27%, 35%, 29% and 8% when assessed by ACE-27. A substantial dose reduction of docetaxel occurred more often in men with moderate or severe comorbidity as compared to those with no or mild comorbidity. At all comorbidity levels about one-third of men required hospitalization or died during treatment with docetaxel. In univariate analysis a higher level of comorbidity was not associated with worse OS (aa-CCI HR 0.99; [95% CI 0.87%1.13], p = 0.93; ACE-27: HR 0.96; [95% CI 0.79%1.17], p = 0.69).
Proste vsebinske oznake		rak prostate metastaziran proti kastraciji odporni rak prostate kemoterapija pridružene bolezni metastatic castration-resistant prostate cancer prostate cancer comorbidity chemotherapy